Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 78.1%

Neg 0% Neu 0% Pos 78.1%

Barclays analyst Etzer Darout maintains Iovance Biotherapeutics (NASDAQ:IOVA) with a Overweight and raises the price target from $11 to $13.